Sitagliptin can prevent the development of NAFLD in obese diabetic mice under lipopolysaccharides existence.
AASLD LiverLearning®, Keisuke Yokohama, 195596
Treatment of type-1 hepatorenal syndrome with pentoxifylline: a randomized placebo controlled, blinded pilot clinical trial
AASLD LiverLearning®, Jonathan Stine, 195341
Nuclear expression of p53-binding protein 1, a DNA damage response molecule, is increased in NAFLD liver
AASLD LiverLearning®, Ryoma Nakashima, 195597
Global Deletion of COX-2 Attenuates Obesity-linked Inflammation but Impairs Hepatic Cholesterol Metabolism in Diet-induced Obesity
AASLD LiverLearning®, Saraswathi Viswanathan, 195612
Promoting effect of connective tissue growth factor (CTGF) in hepatocellular carcinoma via the interaction with hepatic stellate cells and potential of anti-CTGF neutralizing antibody therapy.
AASLD LiverLearning®, Yuki Makino, 195357
Global characterization of gene expression regulation by clinical candidates liraglutide, elafibranor and obeticholic acid in a diet-induced obese mouse model with biopsy-confirmed NASH
AASLD LiverLearning®, Kristoffer Rigbolt, 195613
disruption of the homeostasis in lipid metabolism by knock-down of bile salt export pump may be involved in NASH pathogenesis in mouse model
AASLD LiverLearning®, Kazuya Okushin, 195628
PD-1H is a Novel Negative Checkpoint Regulator for Hepatocellular Carcinoma Immunotherapy
AASLD LiverLearning®, Su Jong Yu, 195373
Patients with Non-alcoholic Fatty Liver Disease (NAFLD) and Depression Have Altered TGF-b Signaling in their Visceral Adipose Tissue (VAT)
AASLD LiverLearning®, Zobair Younossi, 195629
Prevalence and Factors Associated with Cardiovascular Events and Mortality among 21,984 Veterans with Cirrhosis
AASLD LiverLearning®, Marina Serper, 195644
Bilateral function of Mdm2 in the carcinogenesis and progression of hepatocellular carcinoma.
AASLD LiverLearning®, Yuki Makino, 195389
Prospective validation of hepatic collagen content for the prediction of clinical disease progression in patients with advanced fibrosis due to NASH
AASLD LiverLearning®, Zachary Goodman, 195645
Low incidence of HBV reactivation and consequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapy
AASLD LiverLearning®, Akihiro Tamori, 195405
Novel multicenter validation of association between decline in MRI-PDFF and histologic response: A secondary analysis of FLINT Trial
AASLD LiverLearning®, Rohit Loomba, 195661
Improvement in Hepatic Transaminases Over 12 Months After Single Procedure Duodenal Mucosal Resurfacing in Type 2 Diabetes Patients
AASLD LiverLearning®, Annieke van Baar, 195676
Liver stiffness measurement after complete viral response in predicting hepatoma development for patient with hepatitis B virus-related cirrhosis underwent anti-viral therapy
AASLD LiverLearning®, Ching-Hung Wang, 195421
Nonalcoholic steatohepatitis: modulation of histological phenotype by the missense Thr174Met (rs4762) polymorphism of the angiotensinogen (AGT) gene
AASLD LiverLearning®, Yusuf Yilmaz, 195677
Clinical features and risk factors associated with NAFLD in non-obese type 2 diabetes patients
AASLD LiverLearning®, Takeshi Ichikawa, 195692
High Rates of Current & Past HBV Infection with Increasing Age and in Foreign-Born: Importance of Hepatitis Core Antibody Testing
AASLD LiverLearning®, Su Wang, 195437
Fatty Liver Prevalence in Hepatitis C patients after Sustained Virological Response with Direct-Acting Antivirals
AASLD LiverLearning®, Mazen Noureddin, 195693
Macrophage specific delivery of TNF-α siRNA complexed with schizophyllan inhibits inflammation and fibrosis in a murine NASH model
AASLD LiverLearning®, Terumi Takahara, 195708
Electronic Alerts Increase Screening for Chronic Hepatitis B: A Randomized, Double-Blind, Controlled Trial
AASLD LiverLearning®, Eric Chak, 195453
Quantification of hepatic steatosis in patients undergoing liver resection: A comparative study of preoperative controlled attenuation parameter (CAP) versus Fourier transform-infrared spectroscopy (FTIR) and histopathological estimation (HPE) on surgical
Development and External Validation of Prognostic Nomogram for Acute Decompensation of Chronic Hepatitis B Cirrhosis
AASLD LiverLearning®, Fangyuan Gao, 195469
Plasma metabolites for de novo lipogenesis and pharmacodynamic activity of acetyl-CoA carboxylase inhibitor GS-0976
AASLD LiverLearning®, Jacqueline Tarrant, 195725
PNPLA3 but not TM6SF2 polymorphisms were associated with higher degrees of steatosis and liver fibrosis among Brazilian NAFLD patients
AASLD LiverLearning®, Claudia Oliveira, 195728
Cathepsin L inhibitor improves liver regeneration impaired in fibrotic liver.
AASLD LiverLearning®, Toshifumi Sato, 195485
The Association of Male Sex Hormone with Severity of Non-alcoholic Fatty Liver Disease: Results from National Health and Nutrition Examination Survey
AASLD LiverLearning®, Hyunseok Kim, 195743
Correlation between of Non Alcoholic Fatty Liver Disease (NAFLD) Fibrosis Score (NFS) and Left Ventricular Mass Index (LVMI) in NAFLD
AASLD LiverLearning®, Hery Djagat Purnomo, 195744
Chitinase 3-like 1 plays a key role in the progression of nonalcoholic steatohepatitis in mice.
AASLD LiverLearning®, Kengo Tomita, 195501
Development of an algorithm for the prediction of cardiovascular events in patients with NAFLD: the role of mean platelet volume
AASLD LiverLearning®, Benjamin Mullish, 195759
Pilot report of the Steatohepatitis Obesity Longitudinal Active Registry and Data Repository (SOLAR-DR), an Innovative Public Healthcare Approach for Patients at Risk for NAFLD and NASH.
AASLD LiverLearning®, Woodie Zachry, 195760
Hepatocyte Notch activation induces liver fibrosis in NASH
AASLD LiverLearning®, Changyu Zhu, 195516
GPR125 as a Novel Hepatocyte Lipotoxicity Mediator in Preclinical Models of Nonalcoholic Fatty Liver Disease
AASLD LiverLearning®, Yi Guo, 195517
Exercise Tolerance is Frequently Preserved in Presence of Exercise Performance Deficits in Non-Alcoholic Fatty Liver Disease (NAFLD): Implications for Exercise Intervention
AASLD LiverLearning®, Zobair Younossi, 195776
Vitamin D significantly decrease lipid accumulation in Nonalcoholic Fatty Liver Disease (NAFLD) in Zebrafish model and affects genes associated with metabolic pathways
AASLD LiverLearning®, Assaf Issachar, 195532
Polymorphisms in TFAM (rs1937) and NOS2 (rs2297518) Which Are Markers of Mitochondrial Dysfunction Are Associated with Significant Hepatic Fibrosis in Non-alcoholic Fatty Liver Disease (NAFLD)
AASLD LiverLearning®, Zobair Younossi, 195533
Cholangiocytes from Patients with Primary Biliary Cholangitis Display The Warburg Effect with Increased Mitochondria, Oxygen Consumption and Glycolytic Activity
AASLD LiverLearning®, Filip Wysokinski, 195293
The effect of saroglitazar treatment on NAFLD Activity Score and Fibrosis Stage in a diet-induced obese mouse model of biopsy-confirmed non-alcoholic steatohepatitis
AASLD LiverLearning®, Andreas Nygaard Madsen, 195549
Nanostring nCounter® transcriptome analysis identifies immunologic mediators of disease progression from non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH) in paraffin-embedded liver tissue
AASLD LiverLearning®, Lucy Golden-Mason, 195564
Protective effect of phosphatidylcholine against lysophosphatidylcholine-induced cytotoxicity in cholangiocytes: a potential therapeutic target in cholangiocarcinoma
AASLD LiverLearning®, Akiko Sugiyama, 195309
Efficacy of the FXR agonist, MET409, in male and female mouse models of NASH and fibrosis
AASLD LiverLearning®, Brandee Wagner, 195565
Novel Mouse Model of Nonalcoholic Steatohepatitis
AASLD LiverLearning®, Ji-Yeon Shin, 195580
Clinical significance of urinary neutrophil gelatinase-associated lipocalin measurement in differentiating various etiologies of acute kidney injury in cirrhotic patients
AASLD LiverLearning®, Eileen Yoon, 195325
Oxidized linoleic acid metabolites (OXLAMs) lead to oxidative stress-induced mitochondrial dysfunction, apoptosis and Nlrp3 inflammasome activation in the liver
AASLD LiverLearning®, Susanne Schuster, 195581
Nivolumab in Sorafenib-Naive and -Experienced Patients With Advanced Hepatocellular Carcinoma (HCC): Survival, Hepatic Safety, and Biomarker Assessments in CheckMate 040
AASLD LiverLearning®, Bruno Sangro, 201326
Eradication of HCV induced by direct-acting antivirals is associated with a 79% reduction in HCC risk.
AASLD LiverLearning®, George Ioannou, 201327
Efficacy And Safety Of Carvedilol In Patients Of Acute-On-Chronic Liver Failure With Small Or No Esophageal Varices - A Placebo Control Open Label Randomised Trial (NCT02583698)
AASLD LiverLearning®, Sumeet Kainth, 201328
Results of ITCH, A Multi-center Randomized Double-blind Placebo-controlled Trial of Maralixibat, an Ileal Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), for Pruritus in Alagille Syndrome (ALGS)
AASLD LiverLearning®, Benjamin Shneider, 201329
LncRNAH19-containing exosomes from cholangiocytes promote cholestatic liver injury in Mdr2 knock out mice
AASLD LiverLearning®, Xiaojiaoyang Li, 201330
Activation of the HDC/histamine axis by reintroduction of mast cells or histamine treatment induces hepatobiliary damage, liver inflammation and fibrosis in Mdr2-/-/HDC-/- double knockout mice
AASLD LiverLearning®, Laura Hargrove, 201331
Lysosomal nitrosative stress: A novel mechanism for obesity-associated hepatic insulin resistance
AASLD LiverLearning®, Ling Yang, 201332
A novel mechanism involving NKT17 and NKT1/2 subsets in different phases of non-alcoholic fatty liver disease
AASLD LiverLearning®, Idania Marrero, 201342
Lipolysis and lipophagy pathways work in tandem to catabolize lipid droplets in hepatocytes.
AASLD LiverLearning®, Micah Schott, 201343
Identification of a novel transcriptional mechanism by which obeticholic acid upregulates hepatic SR-BI expression in hyperlipidemic hamsters
AASLD LiverLearning®, Jingwen Liu, 201344
OX40 mediates crosstalk between intrahepatic innate and adaptive immunity and promotes nonalcoholic steatohepatitis (NASH) development
AASLD LiverLearning®, Dong Zhang, 201345
CM-101, a novel CCL24 blocking monoclonal antibody ameliorates hepatic injury in NASH induced mouse model
AASLD LiverLearning®, Ziv Ben-Ari, 201346
Significant anti-fibrotic efficacy of EDP-305, a highly potent and selective farnesoid X receptor (FXR) agonist, in a rat model of thioacetamide-induced liver fibrosis and cirrhosis
AASLD LiverLearning®, Li-Juan Jiang, 201347
Phenotype and genotype analysis of metabolic liver disease in half million US Veterans enrolled in the Million Veteran Program (MVP) megabiobank
AASLD LiverLearning®, Marina Serper, 201348
Market Competition Standardizes Liver Transplant Waitlist Management Practices
AASLD LiverLearning®, Yanik Bababekov, 201358
Trends in pregnancy in women with liver disease: 1983 - 2017
AASLD LiverLearning®, Tiong Yeng Lim, 201359
Serum soluble programmed cell death 1 level as a key predictor for spontaneous functional cure of chronic hepatitis B patients
AASLD LiverLearning®, Hui-Han Hu, 201360
Serum HBV RNA level predicts response to peginterferon add-on therapy for HBeAg-positive chronic hepatitis B
AASLD LiverLearning®, Margo van Campenhout, 201361
REAL-B (Real-world Effectiveness from the Asia Pacific Rim Liver Consortium for HBV) - A Risk Score for the Prediction of Hepatocellular Carcinoma (HCC) in Chronic Hepatitis (CHB) Patients Treated with Oral Anti-HBV Therapy
AASLD LiverLearning®, Mindie Nguyen, 201362
Polymorphism of HLA-DRB1 3’UTR (rs9272105), GRIK1 (rs455804), KIF18 (rs17401966) are associated with spontaneous HBsAg seroclearance in HBeAg seronegative chronic hepatitis B carriers.
AASLD LiverLearning®, Wen-Juei Jeng, 201363
Prevalence of hepatitis D viremia among injection drug users in San Francisco
AASLD LiverLearning®, Parag Mahale, 201364
Inhibition of hepatic senescence decreases biliary proliferation and liver fibrosis in vitro and in the Mdr2-/- mouse model of primary sclerosing cholangitis (PSC).
AASLD LiverLearning®, Tina Kyritsi, 201374
β-catenin and IL-1β dependent CXCL10 production drives progression of disease in a mouse model of Congenital Hepatic Fibrosis
AASLD LiverLearning®, Eleanna Kaffe, 201375
Inhibition of H2 histamine receptor by Vivo-Morpholino treatment decreases mast cell activation, large biliary proliferation, angiogenesis, fibrosis and inflammation in the Mdr2-/- mouse model of primary sclerosing cholangitis
AASLD LiverLearning®, Lindsey Kennedy, 201376
Modelling Primary Sclerosing Cholangitis using Induced Pluripotent Stem Cell-Derived Cholangiocytes and 3-Dimensional Biliary Spheroids
AASLD LiverLearning®, Nidhi Jalan-Sakrikar, 201377
Comparison of Outcomes after DAA therapy among HCV-infected kidney transplant recipients who received grafts from either HCV-positive or negative donors.
AASLD LiverLearning®, Mai Sedki, 201378
Efficacy and Safety of Sofosbuvir/Velpatasvir plus Ribavirin for 12 or 24 Weeks in Genotype 1 or 2 HCV-Infected Japanese Patients with Prior Treatment Failure to DAA-Based Regimens
AASLD LiverLearning®, Shampa De-Oertel, 201379
Hepatitis C Virus (HCV) Reinfection and Injecting Risk Behavior Following Elbasvir (EBR)/Grazoprevir (GZR) Treatment in Participants on Opiate Agonist Therapy (OAT): Co-STAR Part B
AASLD LiverLearning®, Gregory Dore, 201380
The road to elimination of Hepatitis C: Analysis of SVR versus new HCV infections in 91 countries
AASLD LiverLearning®, Andrew Hill, 201390
Dynamics and Characterization of DAA Treatment Induced Serum AFP Reduction in HCV-infected Patients without Hepatocellular Carcinoma (HCC)
AASLD LiverLearning®, Mohit Mittal, 201391
Significantly Improved Liver Transplant Waitlist Survival Among Chronic Hepatitis C Virus Patients After Introduction of Direct Acting Antiviral Therapies
AASLD LiverLearning®, Kellie Young, 201392
Hepatitis C virus-induced epigenetic changes associated with hepatocarcinogenesis persist following viral cure
AASLD LiverLearning®, Frank Jühling, 201393
MicroRNA-130a Regulates HCV and HBV Replication through the PKLR/pyruvate Pathway
AASLD LiverLearning®, Xiaoqiong Duan, 201394
Identification of Novel HCV Genotype and Subtypes in Patients Treated with Sofosbuvir Based Regimens
AASLD LiverLearning®, Charlotte Hedskog, 201395
Proposal of GALADUS Score: Combining liver ultrasound with serum based biomarkers for Hepatocellular Carcinoma Surveillance
AASLD LiverLearning®, Benyam Addissie, 201396
L-Ornithine L-Aspartate In Acute Overt Hepatic Encephalopathy
AASLD LiverLearning®, Sandeep Sidhu, 201406
Sarcopenia and Opiate Use May Be Modifiable Risk Factors for Incident Overt Hepatic Encephalopathy: A Prospective Study
AASLD LiverLearning®, Elliott Tapper, 201407
Association of Aspirin Therapy with Reduced Risk of Hepatocellular carcinoma in Patients with Chronic Hepatitis B
AASLD LiverLearning®, Teng-Yu Lee, 201408
HNF4α Gene Signature Can Accurately Predict Stage Specific Disease Progression In Cirrhosis And Hepatocellular Carcinoma
AASLD LiverLearning®, Udayan Apte, 201409
Phenotypic diversity spanning the spectrum of hepatocyte differentiation impacts the outcome of patients with β-catenin-mutated hepatocellular carcinomas.
AASLD LiverLearning®, Orlando Musso, 201410
The incidence of hepatocellular carcinoma is not increased in individuals with chronic hepatitis C after SVR with interferon-free regimens compared with interferon-containing regimens: an ERCHIVES study
AASLD LiverLearning®, Darrick Li, 201411
Neoangiogenic transcriptomic signature identifies HCCs with worse therapeutic outcome
AASLD LiverLearning®, Alberto Borghi, 201412
EZH2 Histone Methyltransferase Promotes TGFβ Dependent Fibrogenic Genes In Vitro and Liver Fibrosis In Vivo
AASLD LiverLearning®, Rosa Martin Mateos, 201422
Modeling compound-induced hepatic fibrosis in vitro using three-dimensional liver tissue constructs
AASLD LiverLearning®, Leah Norona, 201423
Heat Shock Transcription Factor 1 (HSF1), a key cellular proteostasis regulator, is crucial for resolution of liver fibrosis in mice
AASLD LiverLearning®, Asmita Choudhury, 201424
Tyrosine kinase SYK is a potential therapeutic target for liver fibrosis
AASLD LiverLearning®, Jian Hong, 201425
ω3 polyunsaturated fatty acids(PUFA) lipid emulsions are safe and effective to reduce endotoxemia and sepsis in patients with Acute on Chronic Liver Failure -A randomised controlled trial.(NCT 02691533)
AASLD LiverLearning®, Anand Kulkarni, 201426
Prediction of Fungal Infection Development and Their Impact on Survival using the NACSELD Cohort
AASLD LiverLearning®, Jasmohan Bajaj, 201427
Early introduction of a combination of low dose terlipressin and noradrenaline as vasopressors is superior to high dose noradrenaline alone in patients of cirrhosis with septic shock(NCT02468063).
AASLD LiverLearning®, Vikash Prakash, 201428
Application of human NASH-based transcriptome and metabolome profiles in preclinical models for the translational study of drug effects on liver fibrosis
AASLD LiverLearning®, Martine Morrison, 201438
Down-regulation of hepatic MBOAT7 by hyperinsulinemia favors steatosis development
AASLD LiverLearning®, Marica Meroni, 201439
Responding to metabolic demand: Key role for Thioesterase superfamily member 2 in the hepatic partitioning of fatty acids between oxidative and synthetic pathways
AASLD LiverLearning®, Michele Alves-Bezerra, 201440
The role of X-box binding protein 1 in the hepatic response to fasting and refeeding in mice
AASLD LiverLearning®, Anne Henkel, 201441
Autophagic changes of both adipose tissues and the liver induced by high fat diet feeding contribute to hepatic lipid accumulation
AASLD LiverLearning®, Sadatsugu Sakane, 201442
Level of a Prototypical Splicing Factor is Severely Diminished in Hepatocytes of Non-alcoholic Steatohepatitis Patients
AASLD LiverLearning®, Raiya Sarwar, 201443